Show simple item record

dc.contributor.authorAwan, Farrukh T.
dc.contributor.authorKochuparambil, S. Thomas
dc.contributor.authorDeRemer, David
dc.contributor.authorCumpston, Aaron
dc.contributor.authorCraig, Michael
dc.contributor.authorJillella, Anand
dc.contributor.authorHamadani, Mehdi
dc.date.accessioned2012-10-26T20:30:44Z
dc.date.available2012-10-26T20:30:44Z
dc.date.issued2012-04-10en_US
dc.identifier.citationJ Oncol. 2012 Apr 10; 2012:931071en_US
dc.identifier.issn1687-8469en_US
dc.identifier.pmid22570654en_US
dc.identifier.doi10.1155/2012/931071en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/787
dc.description.abstractThe combination of filgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood progenitor cell collection. In this paper we describe our experience from two North American transplant centers in a series of patients who received salvage plerixafor while failing chemotherapy and G-CSF mobilization. Patients received a median of two doses of plerixafor salvage upon failure to mobilize adequate number of peripheral blood progenitor cells at neutrophil recovery. The use of plerixafor was associated with a 2.4-fold increase in peripheral blood CD34+ cell count and 3.9-fold increase in total CD34+ cell yield. All patients were able to collect â ¥2 Ã 106 CD34+â cells/kg with this approach. These results were more pronounced in patients with a higher CD34+ cell count at the time of the first plerixafor dose. Interestingly, peripheral blood white blood cell count was not shown to correlate with a response to plerixafor. Our results provide safety and efficacy data for the use of plerixafor in patients who are destined to fail chemomobilization.
dc.rightsCopyright © 2012 Farrukh T. Awan et al.en_US
dc.subjectResearch Articleen_US
dc.titlePlerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilizationen_US
dc.typeArticleen_US
dc.identifier.pmcidPMC3335320en_US
dc.contributor.corporatenameDepartment of Medicine
dc.contributor.corporatenameDepartment of Pharmacology and Toxicology
refterms.dateFOA2019-04-10T00:50:51Z
html.description.abstractThe combination of filgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood progenitor cell collection. In this paper we describe our experience from two North American transplant centers in a series of patients who received salvage plerixafor while failing chemotherapy and G-CSF mobilization. Patients received a median of two doses of plerixafor salvage upon failure to mobilize adequate number of peripheral blood progenitor cells at neutrophil recovery. The use of plerixafor was associated with a 2.4-fold increase in peripheral blood CD34+ cell count and 3.9-fold increase in total CD34+ cell yield. All patients were able to collect â ¥2 Ã 106 CD34+â cells/kg with this approach. These results were more pronounced in patients with a higher CD34+ cell count at the time of the first plerixafor dose. Interestingly, peripheral blood white blood cell count was not shown to correlate with a response to plerixafor. Our results provide safety and efficacy data for the use of plerixafor in patients who are destined to fail chemomobilization.


Files in this item

Thumbnail
Name:
JO2012-931071.pdf
Size:
459.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record